Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation

Seth A. Wander, Aditya Bardia, Steven J. Isakoff et al.|Cancer Research|2022

Cited by 1